Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Synthetic Biology and the Question of Public Participation Case Study: COVID-19 Vaccine Development

Synthetic Biology and the Question of Public Participation : Case Study: COVID-19 Vaccine... [When talking about public participation and the regulatory decision-making process, it is crucial to think about the right time and purpose to involve different stakeholders. The chapter explores circumstantial prerequisites for participatory approaches on the basis of a more recent case study: synthetically produced vaccines against the coronavirus SARS-CoV-2. The COVID-19 pandemic made synthetic biology a global issue—in a way that is unprecedented. Yet, its implementation also poses questions for participation for future vaccine and drug production: How can and should we engage the public on ethical questions of emerging and potentially disruptive technologies during a public health emergency? How do certain focus areas, particularly communication and resources, data management and training, provide valuable avenues in dealing with future emergency applications of SB?] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Synthetic Biology and the Question of Public Participation Case Study: COVID-19 Vaccine Development

Loading next page...
 
/lp/springer-journals/synthetic-biology-and-the-question-of-public-participation-case-study-3yCML08lx0
Publisher
Springer International Publishing
Copyright
© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023
ISBN
978-3-031-16003-5
Pages
47 –53
DOI
10.1007/978-3-031-16004-2_6
Publisher site
See Chapter on Publisher Site

Abstract

[When talking about public participation and the regulatory decision-making process, it is crucial to think about the right time and purpose to involve different stakeholders. The chapter explores circumstantial prerequisites for participatory approaches on the basis of a more recent case study: synthetically produced vaccines against the coronavirus SARS-CoV-2. The COVID-19 pandemic made synthetic biology a global issue—in a way that is unprecedented. Yet, its implementation also poses questions for participation for future vaccine and drug production: How can and should we engage the public on ethical questions of emerging and potentially disruptive technologies during a public health emergency? How do certain focus areas, particularly communication and resources, data management and training, provide valuable avenues in dealing with future emergency applications of SB?]

Published: Mar 16, 2023

Keywords: Pandemic; COVID-19; mRNA Vaccine; Synthetic Vaccines; Emergency Authorization; Communication; Resources; Training

There are no references for this article.